Whitehead Institute for Biomedical Research

American Cyanamid Company

Mark B Feinberg

Richard A Young

David Baltimore

Anna Aldovini

Didier Trono

Carolyn L Weeks-Levy

Patricia Anne Reilly

Raul Andino

Replication-competent recombinant viruses, particularly replication-competent recombinant polioviruses, which include (1) exogenous nucleic acid sequences which encode an exogenous polypeptide and (2) a nucleic acid sequence which encodes an artificial proteolytic cleavage site for a viral or cellular protease which proteolytically processes (cleaves) the precursor protein produced by the parent virus and uses therefor. The recombinant precursor is cleaved into the usual array of constituent proteins, freeing the exogenous polypeptide. Replication-competent recombinant viruses are useful as vaccines against bacterial, viral, fungal and yeast infections, parasitic diseases, cancer and allergies.

Replication-competent recombinant viral vaccines and method of producing

This invention related to constructs comprising mutant HIV genomes having an alteration in a nucleotide sequence which is critical for genomic RNA packaging and non-infectious, immunogenic HIV particles produced by expression of these constructs in mammalian cells. Cell lines which stably produce non-infectious, immunogenic HIV particles are also included. Prophylactic and therapeutic vaccines, diagnostic reagents, and related methods are further described.

Non-infectious HIV particles and uses therefor

Growing community of inventors

San Francisco, CA, United States of America

Mark B Feinberg